Adipogenesis associated Mth938 domain-containing protein (AAMDC)

Adipogenesis associated Mth938 domain-containing protein (AAMDC) is a human protein encoded by the AAMDC gene on chromosome 11. It is characterized by a conserved Mth938 structural domain and has been implicated as an oncogene, particularly in aggressive estrogen receptor-positive breast cancers. AAMDC regulates metabolic enzymes involved in one-carbon folate and methionine cycles as well as lipid metabolism, controlling cell proliferation and oncogenic signaling via activation of the PI3K-AKT-mTOR pathway. Its expression is associated with increased tumor growth, resistance to anti-estrogen therapy, and metabolic reprogramming. In addition to its oncogenic role, AAMDC is predicted to participate in adipogenesis and preadipocyte differentiation, potentially influencing lipid metabolism and cellular signaling. High AAMDC expression has been identified as a vulnerability in breast tumors, conferring sensitivity to PI3K-mTORC1 inhibitors such as dactolisib and everolimus, especially when combined with anti-estrogen therapy.

Other names

Mth938 domain-containing proteinC11orf67PTD015FLJ21035CK067UPF0366 protein C11orf67adipogenesis associated Mth938 domain-containing proteinmth938 domain-containing protein

Indirect: Drugs such as dactolisib and everolimus target the PI3K-AKT-mTOR axis, which is activated downstream of AAMDC overexpression. High AAMDC levels sensitize tumors to these agents, especially in combination with anti-estrogens in breast cancer models.